Analysis
Lycia Therapeutics priced its upsized initial public offering at $18.00 per share for 17,640,000 shares, for expected gross proceeds of about $317.5 million before underwriting discounts, according to the company's pricing announcement. Trading was expected to begin October 23 on the Nasdaq Global Select Market under the ticker LYCA, with closing expected October 26.
Pulse previously covered Lycia's IPO filing, which had targeted a roughly $937.7 million valuation. The pricing itself doesn't restate a valuation figure, but an upsized offering — more shares sold, at or above the initial range — generally signals stronger order-book demand than a downsized or flat pricing would.
“Pulse previously covered Lycia's IPO filing, which had targeted a roughly $937.7 million valuation.”
Underwriters hold a 30-day option to purchase up to an additional 2,646,000 shares at the IPO price, which would push total proceeds higher if exercised in full. That overallotment option is a better gauge of aftermarket demand than the pricing-day numbers alone, since underwriters typically exercise it when the stock is trading at or above the offer price.
Lycia's listing adds to a busy stretch of biotech IPO activity this month, alongside filings from Aspen Neuroscience and others working through the same Nasdaq pipeline. As with any newly public company, LYCA has no trading history yet, and the real test of this pricing comes in the weeks after the quiet period, not on day one.
